ARTICLE | Company News

HemoShear, Takeda in liver disease deal

October 20, 2017 7:21 PM UTC

HemoShear Therapeutics LLC (Charlottesville, Va.) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) partnered to discover and develop therapeutics for liver diseases including non-alcoholic steatohepatitis (NASH). HemoShear will receive undisclosed upfront payments and R&D funding and is eligible for $470 million in milestones, plus royalties.

HemoShear Head of Innovation Brian Wamhoff told BioCentury the partnership has three aims -- to discover and validate targets that could launch new pharmaceutical projects, to explore an undisclosed aspect of NASH biology, and to screen Takeda’s existing preclinical assets for safety and efficacy...